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Atenolol, a β1-adrenergic receptor blocker, is administered orally and its intestinal absorption has re-
cently been indicated to be mediated by carrier protein and reduced markedly by ingestion of some fruit
juices, such as apple and orange juices. This could be postulated to be a problem arising from the in-
teraction of some components of fruit juices with atenolol at a transporter involved in its intestinal
uptake, but the responsible transporter and its interacting components have not been identiﬁed yet. In
an attempt to examine that possibility, we could successfully ﬁnd that human organic cation transporter
1 (OCT1/SLC22A1), which is suggested to be expressed at the brush border membrane of enterocytes, is
highly capable of transporting atenolol. In this attempt, OCT1 was stably expressed in Madin-Darby
canine kidney II cells and the speciﬁc uptake of atenolol by the transporter was found to be saturable,
conforming to the Michaelis-Menten kinetics with the maximum transport rate (Vmax) of 4.00 nmol/min/
mg protein and the Michaelis constant (Km) of 3.08 mM. Furthermore, the OCT1-speciﬁc uptake was
found to be inhibited by various ﬂavonoids, including those contained in fruit juices that have been
suggested to interfere with intestinal atenolol absorption. Particularly, phloretin and quercetin, which are
major components of apple juice, were potent in inhibiting OCT1-mediated atenolol transport with the
inhibition constants of 38.0 and 48.0 mM, respectively. It is also notable that the inhibition by these
ﬂavonoids was of the noncompetitive type. These results indicate that OCT1 is an atenolol transporter
that may be involved in intestinal atenolol uptake and sensitive to fruit juices, although its physiological
and clinical relevance remains to be further examined.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Atenolol is a selective β1-adrenergic receptor blocker that is orally
effective in the treatment of hypertension, angina pectoris, and car-
diac arrhythmias [1–3]. This drug, of which the absorption is rather
moderate with the bioavailability of about 50% [4], has generally
been assumed to be absorbed by simple diffusion in the intestine [5].
However, based on recent ﬁndings of signiﬁcant reductions in its
absorption by simultaneous administration with apple juice [6] and
with orange juice [7], it may be needed to assume that carrier-
mediated uptake transport, which could be inhibited by some con-
stituents of those fruit juices, is involved in its absorption. It may be
possible that the disposition of this hydrophilic drug, which little
undergoes metabolism and is eliminated almost exclusively (90%) by
excretion into the urine in unchanged form after absorption [8], isr B.V. This is an open access article
. Yasujima).regulated by membrane transporters.
Organic anion transporting polypeptide 1A2 (OATP1A2/
SLCO1A2) and OATP2B1/SLCO2B1, which have recently been sug-
gested to be involved in the intestinal uptake of various anionic
drugs [9], can also be inhibited by such plant components, and it
could lead to decreases in the absorption of their substrate drugs
[10,11]. It should be of interest to note that some β1-adrenergic
receptor blockers structurally analogous to atenolol have been
reported to be transported by OATP1A2 and OATP2B1 [12,13], even
though this class of drugs is cationic. Particularly, talinolol is
known as an OATP1A2 substrate, and its absorption is also in-
hibited by ﬂavonoids [12]. Thus, OATP1A2 and OATP2B1 may also
contribute to the absorption of atenolol, but another possibility
could not be excluded that some other transporters for cationic
compounds may participate in that process. We, here, describe our
successful attempt to identify human OCT1/SLC22A1 as an ate-
nolol transporter, which may be involved in intestinal atenolol
absorption. OCT1 is known to be typically expressed in theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of various cationic compounds including endogenous compounds
and drugs, such as tetraethylammonium (TEA), 1-methyl-4-phe-
nylpyrimidine (MPPþ), acetylcholine and metformin [14–16]. Di-
phenhydramine, atropine and desipramine are, on the other hand,
known as its typical inhibitors that are not transported. Recently,
its presence and potential role in drug transport has also been
suggested in the intestine in the brush border and basolateral
membranes.2. Materials and methods
2.1. Materials
[14C]Tetraethylammonium (TEA, 55 mCi/mmol) and [3H]1-me-
thyl-4-phenylpyridinium (MPPþ , 85 Ci/mmol) were obtained from
American Radiolabeled Chemicals (St. Louis, MO, USA), [3H]ate-
nolol (3.3 Ci/mmol) was from Moravek Biochemicals (Mercury
Lane, Brea, CA, USA), and [3H]estrone-3-sulfate (54 Ci/mmol) was
from PerkinElmer (Waltham, MA, USA). Unlabeled atenolol and
Dulbecco’s modiﬁed Eagle’s medium (DMEM) were from Wako
Pure Chemical Industries (Osaka, Japan). Fetal bovine serum (FBS)
was obtained from Invitrogen (Carlsbad, CA, USA). All other re-
gents were of analytical grade and commercially obtained.
2.2. Cell culture
Madin-Darby canine kidney II (MDCKII) cells and human em-
bryonic kidney 293 (HEK293) cells were maintained at 37 °C and
5% CO2 in DMEM supplemented with 10% FBS, 100 U/ml penicillin,
and 100 mg/ml streptomycin.
2.3. Plasmids
The plasmids carrying the cDNAs of OCT1/SLC22A1, OCT2/
SLC22A2, OCT3/SLC22A3, OCTN1/SLC22A4 and OCTN2/SLC22A5 of
human were those prepared in our previous study [17]. The
plasmids carrying the cDNAs of OATP1A2 and OATP2B1 of human
were prepared by using the cDNAs isolated by RT-PCR cloning
from the human small intestine total RNA (Clontech, Mountain
View, CA, USA) in the present study. In brief, an RT reaction was
performed to obtain the cDNA mixture, using 1 mg of the total RNA,
an oligo(dT) primer and ReverTra Ace (Toyobo, Osaka, Japan) as a
reverse transcriptase. The cDNA of OATP1A2 was ampliﬁed by PCR,
using KOD plus polymerase (Toyobo) and the following primers:
forward primer, 5’-CCA GAT TTT AAG ACC AAC GC-3’ and reverse
primer, 5’-TTC AAA GTT CCC CAG TGT AA-3’. These primers were
designed on the basis of the sequence in GenBank (accession
number NM_021094.3). PCR was performed using the following
conditions: predenature at 94°C for 2 min and 33 cycles of
(1) denature at 98°C for 10 s, (2) annealing at 52°C for 20 s, and
(3) extension at 68°C for 90 s. The second PCR was performed
using the PCR product as a template and a forward primer con-
taining XhoI restriction site (underlined), 5′-GAA CTC G AGC AAC
ATG GGA GAA ACT G-3′ and a reverse primer containing XbaI re-
striction site (underlined), 5′-GCT CTA GAG TTG TAC AGC ATG TTC
TC-3′. The ampliﬁed cDNA product was incorporated into pCI-neo
vector (Promega, Madison, WI, USA) at XhoI and XbaI sites, and
the sequence of the ﬁnal product was determined with an auto-
mated sequencer. The cDNA of OATP2B1 (GenBank accession
number NM_007256. (4) was isolated similarly by RT-PCR cloning.
The primers for PCR were as follows: forward primer, 5′-TGC TTC
CTC TCC CCT GCT AAG-3′ and reverse primer, 5′-GAA GGT GAT CCA
GGC GAG TG-3′. The second PCR was performed using the PCR
product as a template and a forward primer containing XhoIrestriction site (underlined), 5′-GAA CTC GAG GTC ATG GGA CCC
AGG ATA G-3′ and a reverse primer containing XbaI restriction site
(underlined), 5′- GTG TCT AGA GGA GGT ACT GCT GTG GC-3′. The
ampliﬁed cDNA product was incorporated into pCI-neo vector at
XhoI and XbaI sites and the sequence of the ﬁnal product was
determined with an automated sequencer.
2.4. Preparation of MDCKII cells stably expressing OCT1
MDCKII cells were transfected with the plasmid carrying the
cDNA of OCT1 by using Lipofectamine 2000 (Invitrogen) as a
transfection reagent, according to the manufacturer’s instructions,
and cultured in DMEM supplemented with 10% FBS and 400 mg/ml
G418 for 2 or 3 weeks. Antibiotic resistant clones were selected
and tested for the transport of [3H]MPPþ as a probe substrate.
2.5. Uptake study in HEK293 cells transiently expressing OCTs, OATPs
and OCTNs
HEK293 cells (2105 cells/ml, 1 ml/well) were grown on 24-
well plates coated with poly-L-lysine for 12 h, transfected with the
plasmid carrying the cDNA of each transporter by using Lipo-
fectamine 2000, and cultured for 36 h for transient expression. The
transient expression of each transporter was conﬁrmed by obser-
ving the speciﬁcally induced uptake of its typical substrate in
HEK293 cells transfected with the plasmid for the transporter. The
substrates were [3H]TEA for OCT1,OCT2, OCT3, OCTN1 and OCTN2,
and [3H]estrone-3-sulfate for OATP1A2 and OATP2B1. The cells in
each well were preincubated in 1 ml of substrate-free uptake
buffer, that is Hanks’ solution (136.7 mM NaCl, 5.36 mM KCl,
0.925 mM CaCl2, 0.812 mM MgSO4, 0.441 mM KH2PO4, 0.385 mM
Na2HPO4, and 25 mM D-glucose) supplemented with 10 mM
HEPES (pH 7.4), for 5 min and uptake assays were started by re-
placing the substrate-free uptake buffer for preincubation with
uptake buffer containing [3H]atenolol (0.25 ml). All the procedures
were conducted at 37 °C. After uptake for 3 min, assays were
stopped by addition of ice-cold substrate-free uptake buffer (2 ml)
and the cells were washed two times with 2 ml of the same buffer.
The cells were solubilized in 0.5 ml of 0.2 M NaOH solution con-
taining 0.5% sodium dodecyl sulfate at room temperature for 1 h
and the associated radioactivity was measured by liquid scintilla-
tion counting, using 3 ml of Clear-sol I (Nacalai Tesque, Kyoto, Ja-
pan) as a scintillation ﬂuid, for the evaluation of uptake. Cellular
protein content was determined by the BCA method (BCA Protein
Assay Reagent Kit; Thermo Fisher Scientiﬁc, Waltham, MA, USA),
using bovine serum albumin as the standard. Uptake assays were
also conducted in mock cells, which were transfected with empty
pCI-neo vector, to estimate nonspeciﬁc uptake.
2.6. Uptake study in MDCKII cells stably expressing OCT1
MDCKII cells stably expressing OCT1 (1.5105 cells/ml, 1 ml/
well) were grown on 24-well plates for 48 h to conﬂuence. The
assays of [3H]atenolol uptake, which was for 3 min in regular ex-
periments, were conducted by the same procedures as those de-
scribed for assays in HEK293 cells transiently expressing OCT1.
[3H]MPPþ was used as a substrate in some experiments to assess
the OCT1-mediated transport characteristics of this typical sub-
strate for comparison with those of [3H]atenolol. To examine the
effect of pH, Hanks’ solution was supplemented with 10 mM MES,
instead of HEPES, and adjusted to pH 5.5. To examine the effect of
ﬂavonoids and some other inhibitors, test compounds were added
only to the uptake solution containing [3H]atenolol so that they
were present in the solution only during uptake period. In ex-
periments to examine the effect of BaCl2 as an agent to depolarize
the plasma membrane, a chloride salt-based buffer (145 mM NaCl,
Fig. 1. Screening of candidate transporters for atenolol in HEK293 cells transiently
expressing each of them. Data are presented as means7S.E. (n¼3), where the
experiments were triplicated in a preparation of cells. The uptake of [3H]atenolol
(100 nM) was evaluated for 3 min at 37°C and pH 7.4. *, po0.05 compared with
uptake in mock cells.
Fig. 2. Time course of the uptake of atenolol in MDCKII cells stably expressing
OCT1. Data are presented as means7S.E. (n¼4), where the experiments were
duplicated in each of 2 preparations of cells, giving 4 as a total number. The uptake
of [3H]atenolol (100 nM) was evaluated at 37°C and pH 7.4 in cells expressing OCT1
(open circle) and in mock cells (closed circle).
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glucose) was used to avoid precipitation of Ba salts. Uptake assays
were also conducted in mock cells, which were transfected with
empty pCI-neo vector, to estimate nonspeciﬁc uptake. The speciﬁc
uptake of atenolol or MPPþ by OCT1 was estimated by subtracting
its uptake in mock cells from that in transporter-transfected cells.
The expression of OCT1 was conﬁrmed by a greater uptake of
[3H]MPPþ (5 nM) in the cells expressing OCT1 (170.1711.1 fmol/
mg protein, n¼4) than in mock cells (12.970.3 fmol/mg protein,
n¼4), where the uptake was evaluated for 3 min at 37 °C and pH
7.4 and the experiments were duplicated in each of 2 preparations
of cells, giving 4 as a total number.
2.7. Data analysis
The saturable transport of atenolol by OCT1 was analyzed by
assuming Michaelis-Menten type carrier-mediated transport re-
presented by the following equation: v¼Vmax s/(Kmþs). The
apparent parameters of the maximum transport rate (Vmax) and
the Michaelis constant (Km) were estimated by ﬁtting this equa-
tion to the experimental proﬁle of the uptake rate (v) versus the
concentration (s) of atenolol as the substrate, using a nonlinear
least-squares regression analysis program, WinNonlin (Pharsight,
Mountain View, CA), and the v-2 as the weight. The value of v was
estimated as the mean of duplicate determinations in a prepara-
tion of cells. The parameters are presented as the means7S.E. of
those estimated in multiple preparations of cells.
Based on the assumption of noncompetitive inhibition, Vmax in
the presence of an inhibitor (Vmax,i) can be related to that in its
absence (Vmax,0), using the inhibitor concentration (i) and the in-
hibition constant (Ki), as follows: Vmax,i¼Vmax,0/(1þ i/Ki). Based on
this equation, the Ki was estimated using the mean values of Vmax,i
and Vmax,0, and the experimentally designated value of i.
When s is much smaller than Km (s « Km), the v in the presence
of noncompetitive inhibitor can be described as follows: v¼v0/
(1þ(i/IC50) n). The half maximal inhibitory concentration (IC50)
was estimated together with the Hill coefﬁcient (n) by ﬁtting this
equation to the experimental proﬁle of v versus i, with v in the
absence of inhibitors (v0) ﬁxed at the observed value.
Experimental data are presented as the means7S.E. Statistical
analysis was performed by using Student's t-test or, when multiple
comparisons were needed, analysis of variance followed by Dun-
nett's test, with po0.05 considered signiﬁcant.3. Results
3.1. Identiﬁcation of OCT1 as a transporter capable of transporting
atenolol
To identify transporters that are capable of transporting ate-
nolol, we had several candidate transporters, which are reportedly
expressed in the small intestine [18,19], expressed transiently in
HEK293 cells and examined the cellular uptake of atenolol. As
shown in Fig. 1, the uptake of atenolol was, compared with that in
mock cells, increased most extensively in the cells expressing
OCT1 and, to a lesser extent, in those expressing OCT2, indicating
the ability of these transporters to transport atenolol, but not in
those expressing the other transporters. Because OCT1 has been
suggested to be present in the brush border membrane of en-
terocytes [20], while OCT2 has been suggested to be present in the
basolateral membrane [18], we assumed that OCT1 could be a
transporter that may be involved in the intestinal uptake of ate-
nolol and conducted further characterization of its function for
atenolol transport.3.2. Functional characterization of OCT1 as an atenolol transporter
For more detailed characterization of atenolol transport by
OCT1, we prepared MDCKII cells stably expressing OCT1 and ﬁrst
examined the time course of the uptake of atenolol. As shown in
Fig. 2, the uptake of atenolol in the cells expressing OCT1 was
much greater than that in mock cells, consistent with the sug-
gestion in HEK293 cells transiently expressing OCT1 that atenolol
is a good substrate of this transporter, and increased in proportion
to time up to 3 min. Based on this time course, we set the uptake
period to be 3 min in subsequent experiments to evaluate atenolol
transport across the plasma membrane within the initial uptake
phase.
The concentration-dependent proﬁle of the rate of speciﬁc
atenolol uptake by OCT1 was found to be highly saturable and
conformed to the Michaelis-Menten kinetics with a Km of 3.08 mM
and a Vmax of 4.00 nmol/min/mg protein (Fig. 3A). The speciﬁc
uptake rate of atenolol by OCT1 was, when assessed at 100 nM as a
low concentration below the Km and within the linear phase of the
Michaelis-Menten kinetics, sensitive to pH, being signiﬁcantly re-
duced to 65.774.5 from 193.273.9 fmol/min/mg protein
(means7S.E., n¼4, po0.05) when pH was lowered to 5.5 from
7.4, and was also sensitive to the membrane potential, being sig-
niﬁcantly reduced to 149.476.6 from 321.574.9 fmol/min/mg
protein (means7S.E., n¼4, po0.05) by depolarization of the
plasma membrane by the addition of BaCl2 in the medium. Since
atenolol is supposed to be almost completely ionized in the range
of pH 5.5 to pH 7.4, based on its reported pKa of 9.4 [21], the status
of its ionization was unlikely to be a factor to affect its transport in
the present study. These characteristics of atenolol transport were
Fig. 3. Kinetic analysis of atenolol transport by OCT1 stably expressed in MDCKII cells. (A) The rate of speciﬁc atenolol uptake by OCT1 was evaluated for 3 min at 37 °C and
pH 7.4 at varied concentrations of atenolol in the absence of ﬂavonoids (closed circles) or in the presence of phloretin (open triangles, 50 mM) or quercetin (open squares,
50 mM). Solid lines show proﬁles based on the respective sets of the mean values of Vmax and Km. The values of Vmax (nmol/min/mg protein) and Km (mM) are 4.0070.22 and
3.0870.17, respectively, for control, 1.7170.12 and 3.0470.26, respectively, in the presence of phloretin, and 1.9670.55 and 3.4670.78, respectively, in the presence of
quercetin. (B) Eadie-Hofstee plots for OCT1-speciﬁc atenolol uptake. (C) The rate of OCT1-speciﬁc uptake of [3H]atenolol (100 nM) was evaluated for 3 min at 37 °C and pH
7.4 in the presence of varied concentrations of phloretin (open triangles) and quercetin (open squares). The values of v0 are 192 and 193 fmol/min/mg protein, respectively, in
experiments using phloretin and quercetin. The values of IC50 (mM) and n are 28.474.7 and 1.170.1, respectively, for phloretin, and 35.379.1 and 1.370.2, respectively, for
quercetin. The uptake rate was estimated as the mean of duplicate determinations in a preparation of cells. The data of uptake rate and parameters are presented as
means7S.E. of those estimated in 3 preparations of cells (n¼3).
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[14] and also with those observed in the present study for the
speciﬁc uptake of MPPþ as its typical substrate. The speciﬁc up-
take rate of MPPþ (5 nM), which was evaluated for 3 min, was
reduced to 21.571.0 from 56.673.7 fmol/min/mg protein
(means7S.E., n¼4, po0.05) when pH was lowered to 5.5 from
7.4, and was reduced to 42.670.9 from 98.171.5 fmol/min/mg
protein (means7S.E., n¼4, po0.05) by depolarization of the
plasma membrane by BaCl2. The experiments to assess the effects
of pH and membrane depolarization were duplicated in each of
2 preparations of cells, giving 4 as a total number.
3.3. Effect of phloretin and quercetin on atenolol uptake by OCT1
stably expressed in MDCKII cells
We then examined the effect of phloretin and quercetin, which
are the major ﬂavonoids contained in apple juice [22], on OCT1-
speciﬁc atenolol uptake in MDCKII cells stably expressing the
transporter, because the absorption of atenolol is reportedly re-
duced most extensively by apple juice [6]. As shown in Fig. 3A,
both phloretin and quercetin inhibited OCT1-speciﬁc atenololuptake potently by reducing Vmax without altering Km at their
concentration of 50 mM. Therefore, as shown more clearly by Ea-
die-Hofstee plots in Fig. 3B, both phloretin and quercetin were
suggested to inhibit OCT1 noncompetitively, and the Ki values of
these ﬂavonoids were estimated to be 38.0 and 48.0 mM respec-
tively. These values were comparable with the IC50 values of
28.474.7 and 35.379.1 mM for the respective ﬂavonoids, con-
ﬁrming their noncompetitive inhibitory actions on OCT1 (Fig. 3C).
A recent study by Mandery et al. indicated no inﬂuence of quer-
cetin on MPPþ transport by OCT1 [23]. However, the OCT1-speciﬁc
uptake rate of MPPþ (5 nM) was also found to be inhibited by
quercetin in the present study, being reduced to 34.270.5 fmol/min/
mg protein in the presence of quercetin from 58.576.1 fmol/min/mg
protein in its absence (means7S.E., n¼4, po0.05), where the ex-
periments were duplicated in each of 2 preparations of cells, giving
4 as a total number. It is also notable that quercetin was found to
inhibit the OCT1-speciﬁc transport of DAPI, a ﬂuorescent probe
substrate, in our previous study [24]. Therefore, although the reason
why Mandery et al. could not observe the inﬂuence of quercetin on
MPPþ transport by OCT1 is unknown, our ﬁndings strongly suggest
that OCT1 is most likely to be sensitive to quercetin.
Fig. 4. Effect of various compounds on the uptake of atenolol by OCT1 stably expressed in MDCKII cells. (A) The speciﬁc uptake of [3H]atenolol (100 nM) was evaluated for
3 min at 37 °C and pH 7.4 in the presence of a ﬂavonoid (10 mM for kaempferola and 100 mM for the others) or in its absence. Q-D-glc, quercetin-3β-D-glucoside. The control
value of speciﬁc uptake rate was 204 fmol/min/mg protein. (B) The speciﬁc uptake of [3H]atenolol (100 nM) was evaluated for 3 min at 37 °C and pH 7.4 in the presence of a
drug (100 mM) or in its absence. The control value was 126 fmol/min/mg protein. Data are presented as means7S.E. (n¼4), where the experiments were duplicated in each
of 2 preparations of cells, giving 4 as a total number. *, po0.05 compared with control.
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stably expressed in MDCKII cells
To assess the function of OCT1 as an atenolol transporter in
more detail, we here examined the effect of various compounds,
including phloretin, quercetin, and several other ﬂavonoids on
OCT1-speciﬁc atenolol uptake in MDCKII cells stably expressing
the transporter. Kaempferol, which is another major ﬂavonoid
contained in apple juice, was found to inhibit OCT1-speciﬁc ate-
nolol uptake signiﬁcantly at a rather low concentration of 10 mM
(Fig. 4A), although its effect could not be examined at higher
concentrations because of the limitation of its solubility. Hesper-
etin, which is a major ﬂavonoid in orange juice, exhibited an in-
hibitory action comparable to those of phloretin and quercetin at
its concentration of 100 mM. Phlorizin, quercetin-3ß-D-glucoside
and hesperidin, which are the glucosides of phloretin, quercetin
and hesperetin, respectively, also exhibited inhibitory activities
comparable to those of their aglycones [22]. Baicalein, which is a
ﬂavonoid contained in Scutellaria baicalensis [25], exhibited the
most potent inhibitory activity, although baicalin as its glycoside
exhibited an only moderate inhibitory activity.
The speciﬁc uptake of atenolol was inhibited by quinidine
(Fig. 4B), suggesting that atenolol is likely to be competed by this
OCT1 substrate [14]. On the other hand, N-methyl nicotinamide
(NMN), which is known not to inhibit OCT1 activity at this con-
centration [14], did not affect atenolol uptake by OCT1. OCT1-
speciﬁc atenolol uptake was also found to be inhibited by several
cationic drugs including ß1-adrenergic receptor blockers analo-
gous to atenolol, but not by anionic drugs. These ß1-adrenergic
receptor blockers may also be transported by OCT1.4. Discussion
We here have described the novel function of OCT1 as an ate-
nolol transporter. OCT1 is well known to be involved in the
elimination of various organic cationic compounds in the liver
[18]. Therefore, OCT1 may be also in operation for atenolol uptake
in the liver. However, the role of this process in the elimination of
atenolol is unclear, because atenolol is known to be almost ex-
clusively excreted into the urine from the kidney [4,8]. Recently,
OCT1 is reported to be localized to the apical membrane in po-
larized Caco-2 cells, which are widely used as a model of the
human small intestinal epithelial cell [20,26]. However, thelocalization of OCT1 in the epithelial cells in the human tissue
remains inconclusive, because it has also been suggested that
OCT1 plays a role in exporting its substrates across the basolateral
membrane in the intestine as well as liver and kidney [18,27].
Taken all these together, OCT1 may contribute to the transport of
cationic compounds at both the apical and basolateral membranes
in enterocytes.
Fruit juices have been known to inhibit enzymes involved in
metabolism and transporters involved in drug absorption in the
intestine [28–30]. Some components of grapefruit juice have been
shown to be potent inhibitors of cytochrome P450 (CYP) 3A4, one
of the major drug metabolism enzymes [31]. Furthermore, OATPs,
which could be involved in the absorption of various anionic drugs
in the intestine, has also been suggested to be inhibited by con-
stituents of fruit juices [10–13]. It was previously reported that the
plasma concentrations of atenolol are signiﬁcantly decreased by
co-administration of apple juice and orange juice [6,7]. According
to pharmacokinetic analysis, Cmax and AUC were signiﬁcantly re-
duced by 68% and 81%, respectively, by apple juice and by 49% and
40%, respectively, by orange juice. However, the half life of its
elimination was not changed [6,7]. This suggested that apple and
orange juices only affected the absorption process, but not the
elimination process. Our present study showed that OCT1-medi-
ated atenolol transport can be inhibited by various ﬂavonoids,
including those in apple and orange juices. In addition, inhibition
by phloretin and quercetin, which are the major components of
apple juice [22,32], were found to be noncompetitive. This would
be a ﬁnding to support the suggestion that OCT1 participates in
atenolol absorption in the small intestine. Although OATP2B1,
which is also known to be inhibited by fruit juices, has been
suggested to be involved in the absorption of some β1-adrenergic
receptor blockers [13], its genetic variation is reported not to affect
the disposition of atenolol [6] and, furthermore, we could not
detect transport activity of OATP1A2 and OATP2B1 for atenolol
(Fig. 1).
In conclusion, we have successfully identiﬁed OCT1 as an ate-
nolol transporter. Atenolol absorption in the small intestine may
be mediated by OCT1 rather than OATP1A2 and OATP2B1, which
have been suggested to be involved in the absorption of some β1-
adrenergic receptor blockers. The transport activity of OCT1 was
found to be reduced by phloretin and quercetin, which are the
major components of apple juice, and also by several other ﬂa-
vonoids. This could provide a possible molecular basis for the
mechanism behind the inhibition of atenolol absorption by fruit
Y. Mimura et al. / Biochemistry and Biophysics Reports 2 (2015) 166–171 171juices, although the effect of those ﬂavonoids and also some ty-
pical OCT1 inhibitors on atenolol absorption needs to be assessed
in humans to clarify the role of OCT1 in atenolol absorption and
the role of ﬂavonoids in the inhibition of atenolol absorption by
apple juice in the future.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at doi:10.1016/j.bbrep.2015.06.005.References
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